Comparison of the coagulation potential of lyophilized blood plasma virus-inactivated by two different methods: 616.151.5

Abstract

Summary. Introduction. Fresh frozen plasma (FFP) is one of the most common blood components used today in clinics for medical care of bleeding and severe coagulopathies. Unlike virus-inactivated frozen plasma, sublimated (lyophilized) plasma can be stored at room temperature, and recovery before transfusion usually requires less time. Objectives: to assess the coagulation potential of lyophilized plasma obtained from virus-inactivated plasma inactivated by 2 methods: using methylene blue + visible light and riboflavin + ultraviolet radiation of spectrum B. Materials/Methods. Analysis of 100 samples of lyophilized plasma, virus-inactivated by 2 methods, was carried out. The effect of lyophilization on the level of coagulation factors and coagulation parameters in virus- inactivated plasma was studied. For comparative evaluation, 150 samples of FFP were analyzed as a control. Results. Using both technologies for inactivation of lyophilized virus-inactivated plasma, a decrease in the content of V and VIII factors was found both in relation to the FFP and in relation to the physiological norm. Lyophilization of virus-inactivated plasma by various methods led to a slight increasing in blood coagulation parameters — prothrombin time and activated partial thromboplastin time. The rest of the parameters remained within normal limits. There were no significant differences in parameters between plasma samples inactivated by different methods. Conclusions. According clinical properties, virus-inactivated lyophilized plasma can serve as an alternative to FFP, but more studies are needed to clarify the comprehensive aspects of its use.

References:

1. Bundesärztekammer (BÄK). BÄK: cross-sectional guidelines for therapy with blood components and plasma derivatives. Transfus Med Hemother. 2009;36(6):345–492. 

2. Hellstern P., Haubelt H. Indications for plasma in massive transfu- sion. Thromb Res. 2002;107(Suppl 1): S19–22. DOI: 10.1016/s0049– 3848(02)00147–0. 

3. American Association of Blood Banks, American Red Cross, Ame- rica’s Blood Centers, and Armed Services Blood Program. Circu- lar of information for the use of human blood and blood compo- Bethesda (MD): American Association of Blood Banks, 2009. 16 р. Available at: https://www.redcross.org/content/dam/red- cross/atg/PDF_s/GuideToServices.pdf. 

4. Gonzalez E. A., Moore F. A., Holcomb J. B. et al. Fresh frozen plasma should be given earlier to patients requiring mas- sive transfusion. J Trauma. 2007;62(1):112–9. DOI: 10.1097/01. ta.0000250497.08101.8b. 

5. Busch M., Kleinman S., Nemo G. Current and emerging infec- tious risks of blood transfusion. JAMA. 2003;289(8):959–62. DOI: 1001/jama.289.8.959. 

6. Zhiburt E.B., Kopchenko T.G., Gubanova M.N. Inactivation of viruses in the plasma dose for transfusion. Transfuziologiya. 2008;9(2):36–48. (In Russ.). 

7. Williamson L. M., Cardigan R., Prowse C. V. Methylene blue treated fresh-frozen plasma: what is its contribution to blood safety? Transfusion. 2003;43(9):1322–9. DOI: 10.1046/j.1537– 2995.2003.00483.x. 

8. Singh Y., Sawyer L.S., Pinkoski L.S. et al. Photochemical treatment of plasma with amotosalen and long-wavelength ultraviolet light inactivates pathogens while retaining coagulation function. Trans- fusio 2006;46(7):1168–77. DOI: 10.1111/j.1537–2995.2006.00867.x. 

9. 
Russian Federation Government Decree dated of January 26, 2010 N 29 (ed. of 09/04/2012) On the approval of technical regula- tions on the safety requirements of blood, its products, blood- substituting solutions and technical means used in transfusion- infusion therapy. Moscow, 2010. (In Russ.). Available at: https:// ru/doc/postanovlenie-pravitelstva-rf-ot-26012010-n-29. 

10. European Directorate for the Quality of Medicines and Health Care. Guide to the preparation, use and quality assurance of blood components. 18th Strasbourg: Council of Europe Publish- ing, 2015. 534 р. 

11. Ragimov A.A., Shcherbakova G.N. Infusion-transfusion therapy: a guide. Moscow: GEOTAR-Media, 2021. 256 рp. (In Russ.). 

12. Mamaev A. N., Kudlai D. A. Statistical methods in medicine. Moscow: Prakticheskaya medicina, 2021. 136 рp. (In Russ.).
13. Shuja F., Shults C., Duggan M. et al. Development and tes- ting of freeze-dried plasma for the treatment of trauma- associated coagulopathy. J Trauma. 2008;65(5):975–95. DOI: 10.1097/TA.0b013e3181801cd9.
14. Heiden M., Seitz R. Quality of therapeutic plasma requirements for marketing authorization. Thromb Res. 2002;107(Suppl 1): S47– DOI: 10.1016/s0049–3848(02)00152–4.
15. Maurin O., Martinaud C., Boulesteix G. et al. Management of bleeding in a child with haemophilia in Africa with freeze- dried plasma. Haemophilia. 2012;18(1) e:38–9. DOI: 10.1111/j.1365– 2516.2011.02699.x.
16. Krutvacho T., Chuansumrit A., Isarangkura P. et al. Response of hemophilia A with bleeding to fresh dry plasma. Southeast Asian J Trop Med Public Health. 1993;24(Suppl 1):169–73.
17. Shuja F., Finkelstein R.A., Fukudome E. et al. Development and testing of low-volume hyperoncotic, hyperosmotic spray-dried plasma for the treatment of trauma-associated coagulopathy. J Trauma. 2011;70(3):664–71. DOI: 10.1097/TA.0b013e31820e83be.
18. Glassberg E., Nadler R., Gendler S. et al. Freeze-dried plasma at the point of injury: from concept to doctrine. Shock. 2013;40(6):444– 50. DOI: 10.1097/SHK.0000000000000047.
19. Martinaud C., Ausset S., Deshayes A. V. et al. Use of freeze- dried plasma in French intensive care unit in Afghani- stan. J Trauma. 2011;71(6):1761–4; discussion 1764–5. DOI: 10.1097/TA.0b013e31822f1285.
20. Sailliol A., Plang S., Martinaud C. et al. Hemovigilance et secu- rite transfusionnelle en operation exterieure. Transfus Clin Biol. 2014;21(4–5):229–33. DOI: 10.1016/j.tracli.2014.09.001.
21. Shlaifer A., Siman-Tov M., Radomislensky I. et al. Prehospital administration of freeze-dried plasma, is it the solution for trauma casualties? J Trauma Acute Care Surg. 2017;83(4):675–82. DOI: 10.1097/TA.0000000000001569.
22. van Rhenen D., Gulliksson H., Cazenave J.-P. et al., euroSPRITE trial. Transfusion of pooled buffy coat platelet components prepared with photochemical pathogen inactivation treat- ment: the euroSPRITE trial. Blood. 2003;101(6);2426–33. DOI: 10.1182/blood-2002–03–0932.
23. Jensen T., Halvorsen S., Godal H.C. Influence of freeze-drying on the clotting properties of fibrinogen in plasma. Thromb Res. 2002;105(6):499–502. DOI: 10.1016/s0049–3848(02)00057–9.
24. Schoenfeld H., Pruss A., Keller M. et al. Lyophilised plasma: Evaluation of clotting factor activity over 6 days after recon- stitution for transfusion. J Clin Pathol. 2010;63(8):726–30. DOI: 10.1136/jcp.2010.079293.
25. Europe Committee on Blood Transfusion: Guide to the prepara- tion, use and quality assurance of blood components. Recommen- dation No. R (95) 15. 20th Strasbourg, Council of Europe, 2020. 441 рр. Available at: http://www.transfusion.ru/2020/05– 27–2.pdf.
26. Russian Federation Government Decree dated of 22.06.2019 N 797

“On approval of the Rules for the procurement, storage, transpor- tation and clinical use of donor blood and its components and on the recognition as invalid of some acts of the Government of the Russian Federation”. Moscow, 2019. 28 pp. (In Russ.). Available at: http://zdravalt.ru/upload/iblock/d06/797.pdf.

1. Sword-Nilsson A.M., Persson P.O., Johnson U., Lethagen S. Fac- tors influencing factor VIII activity in frozen plasma. Vox Sang. 2006;90(1):33–9. DOI: 10.1111/j.1423–0410.2005.00715.x. 

2. von Heymann C., Keller M.K., Spies C. et al. Activity of clotting factors in fresh-frozen plasma during storage at 4 degrees C over 6 days. Transfusion. 2009;49(5):913–20. DOI: 10.1111/j.1537– 2995.2008.02063.x. 

3. Buchta C., Felfernig M., Hocker P. et al. Stability of coagulation factors in thawed, solvent detergent-treated plasma during stor- age at 4 degrees C for 6 days. Vox Sang. 2004;87(3):182–6. DOI: 10.1111/j.1423–0410.2004.00552.x. 

4. Cardigan R., Lawrie A.S., Mackie I.J., Williamson L.M. The qua- lity of fresh-frozen plasma produced from whole blood stored at 4 degrees C overnight. Transfusion. 2005;45(8):1342–8. DOI: 10.1111/j.1537–2995.2005.00219.x. 

5. Heger A., Romisch J., Svae T.-E. Stability of solvent/detergent treated plasma and single-donor fresh-frozen plasma during 48 h after thawing. Transfus Apher Sci. 2005;33(3);257–67. DOI: 10.1016/j.transci.2005.07.005. 

6. Steil L., Thiele T., Hammer E. et al. Proteomic characterization of freeze-dried human plasma: providing treatment of bleed- ing disorders without the need for a cold chain. Transfusion. 2008;48:2356–63. DOI: 10.1111/j.1537–2995.2008.01856.x. 

7. Bickell W. H., Wall M. J., Pepe P. E. et al. Immediate versus delayed fluid resuscitation for hypotensive patients with penet- rating torso injuries. N Engl J Med. 1994;331(17):1105–9. DOI: 10.1056/NEJM199410273311701.
8. Ley E.J., Clond M.A., Srour M.K. et al. Emergency department crys- talloid resuscitation of 1.5 L or more is associated with increased mortality in elderly and nonelderly trauma patients. J Trauma. 2011;70(2):398–400. DOI: 10.1097/TA.0b013e318208f99b.
9. Hervig T., Doughty H., Ness P. et al. Prehospital use of plasma: the blood bankers’ perspective. Shock. 2014;41(Suppl 1):39–43. DOI: 10.1097/SHK.0000000000000144.
10. Alam H.B., Bice L.M., Butt M.U. et al., Hemostatic Resuscitation Research Group. Testing of blood products in a polytrauma model: results of a multi-institutional randomized preclinical trial. J Trauma. 2009;67(4):856–64. DOI: 10.1097/TA.0b013e3181b5ae75.
11. Capital Region. Ambulance response times. 2012 [cited 2020 Apr 30]. Available at: https://www.region.dk/english/Healthcare- Services/Emergency-Medical-Services/CopenhagenEmergency- medical-services/Documents/Aarsrapport_Praehospitale_Virk somhed_2012_FINAL.pdf.
12. Sunde G.A. Use of blood and plasma in Norwegian Physician staffed Helicopter Emergency Medical Systems (ProHEMS). Available at: https://clinicaltrials.gov/ct2/show/NCT02784951.
13. Jost D. NCT02736812: Pre-hospital Administration of Lyophilized Plasma for Post-traumatic Coagulopathy Treatment (PREHO- PLYO). Available at: https://clinicaltrials.gov/show/nct02736812.
14. Smith I.M., Crombie N., Bishop J.R. et al. RePHILL: protocol for a randomised controlled trial of pre-hospital blood product resuscitation for trauma. Transfus Med. 2018;28(5):346–56. DOI: 10.1111/tme.12486.